drugset / Trial / NCT00120809

Intermittent Preventative Treatment With Sulfadoxine-Pyrimethamine in Gambian Multigravidae

NCT00120809

RandomizedSingle-groupDouble-blindPrevention

Summary

Malaria is particularly harmful during pregnancy causing anemia in the mother and low birth weight which, in turn, increases infant mortality. Thus, the World Health Organization (WHO) now recommends that all pregnant women who live in malaria endemic areas of Africa should receive sulfadoxine-pyrimethamine (SP) at monthly intervals during the second and third trimesters of pregnancy. Malaria is especially severe during first pregnancies and the value of intermittent preventative treatment with SP during first pregnancies has been clearly shown. However, it is less certain whether multigravidae, who are at less risk, also benefit from intermittent preventative treatment with SP. To investigate this, a trial has been conducted in Gambian multigravidae who were given intermittent preventative treatment with SP or placebo during the second and third trimesters. The prevalence of anemia six weeks after delivery, low birth weight and poor outcome of pregnancy in women in each group were studied.

Timeline

Start
2002-07
Primary completion
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject pyrimethamine Small molecule 25 mg
Subject sulfadoxine Small molecule 500 mg

Indications